Search This Website

Friday, August 12, 2022

COVID vaccine: Corbevax approved as Booster Dose for Adults vaccinated with Covaxin, Covishield


COVID vaccine: Corbevax approved as Booster Dose for Adults vaccinated with Covaxin, Covishield

COVID-19 Vaccine: Union fitness Ministry has accept Biological E's Corbevax vaccine as a defense dose for adult PERSONAL who have been inoculated against COVID-19 using Covaxin and Covishield. The accept for the use of Corbevax as a booster dose against COVID comes as a very significant development as this is the first time that a unlike vaccine has been prescribed as compared to the ones that were in primary use against Coronavirus until now. Adult individuals, more than the age of 18 years, can now opt to get theCorbevax vaccine as the defense dose.  

Govt accept Biological E's Corbevax as precaution dose for adults fully vaccinated with either Covishield or Covaxin, official sources say. This is first time booster dose that is different from one used for primary vaccination against Covid has been allowed in India

— Press Trust of India (@PTI_News) August 10, 2022
Apart from being used as a booster dose, Corbevax is the only vaccine and that has been accept for use in 12 to 14-year-old kinds . As part of the authority ongoing vaccination drive, 6.85 crore doses of Corbevax have already been administered to kids falling in the eligible age category .

Corbevax Booster Dose Approved by NTAGI

The accept for Corbevax as India’s 1st heterologous booster shot came following an extensive review by the National Technical Advisory category on Immunisation (NTAGI). Last month, NTAGI accept the use of  Corbevax based on the data shared by its making Biological E - a Hyderabad-based pharmaceutical and vaccines agency . Corbevax is India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine for COVID-19.  

As per a statement issued by BE, the pharmaceutical firm had furnished all the requisite data for its clinical trialsto the Drug Controller General of India (DCGI). The data was totally evaluated by DGCI and its Subject Experts Committee following and that it has been accept  for use as a heterologous COVID-19 booster. The trials were carried out on 416 subjects from 18 to 80 years of age, all of whom had earlier collected two doses of either COVISHIELD or COVAXIN. During the clinical trials, the booster dose of Corbevax showed significant better in the immune reaction and enhanced the safety profile.  

India’s COVID-19 Vaccination Drive in Numbers

As per the data shared by Union fitness Ministry, the ongoing COVID-19 vaccination drive has crossed the 200 crore mark and latest stands at 207.03 crore (2,07,03,71,204) as per acting reports of today. The vaccination in the age category of 12 to 14-year-olds and that started on 16th March 2022, so far, 3.96 crore (3,96,04,796) adolescents have been vaccine against the virus.  

No comments:

Post a Comment